Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Lupin will present data from its Phase 1 a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, from October 17 to October 21, 2025. The presentation, titled 'A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma,” will be featured in the Investigational Immunotherapy session (Presentation Number 1553P). It can be viewed on October 19, 2025, from 09:00 to 17:00 CEST.
LNP3693 is an investigational parenteral STING agonist. The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors.
“This marks another important milestone for us. Following our successful presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, it is a privilege to present the findings of another Phase 1 clinical trial for LNP3693, a STING agonist, at ESMO. ESMO's acknowledgment of the clinical research conducted in India underscores the proficiency of our team in oncology drug discovery, research, and clinical development,' said Vinita Gupta, CEO, Lupin.
The inspection was conducted over a two-week period, from 29 September to 10 October 2025, and concluded with one observation.
Lupin confirmed that it will address the FDA’s observation promptly and submit a comprehensive response within the stipulated regulatory timeframe.
Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The company's consolidated net profit jumped 52.13% to Rs 1,219.03 crore on an 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25.
Shares of Lupin rose 0.11% to end at Rs 1,959.70 on Friday, 10 October 2025.
The 70,000-square-foot facility, spread across five acres, will strengthen Lupin's U.S. supply chain and reduce dependence on imports. It is expected to create more than 200 skilled jobs in Broward County by 2030.
Lupin will receive tax incentives from the State of Florida for its investment and job creation. The company is partnering with Florida Commerce/Select Florida, the City of Coral Springs, and the Greater Fort Lauderdale Alliance on the project.
Mumbai-based Lupin runs 15 manufacturing plants and seven research centers globally. The U.S. remains its largest market, with operations led from Naples, Florida.
Lupin today announced the launch of a strategic partnership program aimed at expanding the reach of PrecisionSphere™ – the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi B.V. (Nanomi). PrecisionSphere™ demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent United States Food and Drug Administration's (U.S. FDA) approval for the first product developed with this platform.
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles, whether in development or already on the market, especially those that could benefit from longer-acting formulations.
“With the validation of PrecisionSphere's capabilities and our proven track record of executing several key strategic partnerships each year, we are ready to expand patient access to advanced LAI treatments through new global strategic collaborations,” said Dr. Fabrice Egros, President – Corporate Development, Lupin. “Our extensive in-house and successful alliance management capabilities will serve as a strategic advantage, as partners strive to deliver innovative LAI solutions to patients at an accelerated pace.”
Lupin said the partnership program is designed to foster collaborations with companies looking to extend their product lifecycles, whether in development or already on the market, especially those that could benefit from longer-acting formulations.
PrecisionSphere™ addresses key compliance issues that lead pharmaceutical companies to lose millions in revenue and experience failed treatment results. Unlike conventional LAI technologies that produce variable particle sizes, this platform allows pharmaceutical companies to manufacture medicines with consistent particle size, shape, and biological properties, leading to improved injectability. It also enables optimized drug levels—the release of consistent drug concentrations throughout the treatment, ranging from weeks to months.
For patients, reduced injection frequency enhances convenience and may lead to greater compliance and potentially better treatment outcomes. For healthcare professionals, this technology would make it possible to control the delivery of a drug at the optimal therapeutic dose during treatment.
Dr Fabrice Egros, president – corporate development, Lupin, said, “With the validation of PrecisionSphere's capabilities and our proven track record of executing several key strategic partnerships each year, we are ready to expand patient access to advanced LAI treatments through new global strategic collaborations. Our extensive in-house and successful alliance management capabilities will serve as a strategic advantage, as partners strive to deliver innovative LAI solutions to patients at an accelerated pace.”
Dr. Shahin Fesharaki, chief scientific officer, Lupin, said, “PrecisionSphere reflects our commitment to innovation and leverages our regulatory expertise, scalable manufacturing capabilities, and flexible collaboration models to lower entry barriers for developing LAIs. This allows partners to efficiently bring advanced LAIs to market across various therapeutic areas and potentially extend the patent life of their products.”